ClinicalTrials.gov
public full text
Public Domain
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease#857055
- A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease#848250
- ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease#866669
- Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)#1125907
- Can supermicrosurgery treat Alzheimer’s disease? - Current evidence and hope / Ashkan Rashad, Behrus Hinrichs-Puladi, Henning Wieker, Jeff Berens, Max Ulbrich, Rainer Röhrig, Frank Hölzle, Kathrin Reetz, Maurice Klein#675409
Record · ID 900385
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive